When Is Magnesium Sulfate Used for Preterm Neuroprotection?

What does the evidence say about magnesium sulfate timing for preterm neuroprotection during pregnancy?

1. ACOG patient guidance says magnesium sulfate may be given when a patient is less than 32 weeks pregnant and at risk of delivery within the next 24 hours. Its fetal purpose is to reduce cerebral palsy and problems with physical movement, not to mature the lungs. 1
2. ACOG's reaffirmed committee opinion notes that individual trials often did not significantly improve their primary composite outcomes, but pooled evidence supports reduced cerebral palsy among survivors. It advises institutions to use a protocol reflecting a major trial's eligibility, regimen, monitoring, and stopping rules. 2
3. A 2024 Cochrane review of six randomized trials, 5,917 participants, and 6,759 fetuses found less cerebral palsy by two years with magnesium sulfate than placebo, risk ratio 0.71, with an estimated 60 patients needing administration for one additional beneficial outcome. Death alone was not significantly reduced. 3
4. FIGO recommends magnesium sulfate when early preterm birth is expected within 24 hours, ideally starting about four hours before birth but still giving it if birth is sooner. It recommends use through 30 weeks and consideration below 32 to 34 weeks, with monitoring during infusion. 4
5. A Cochrane review seeking randomized comparisons among magnesium-sulfate regimens found no eligible completed trials. It could not identify a best loading dose, maintenance dose, duration, or repeat-course strategy, explaining why institutions use protocol-specific regimens. 5

Is magnesium sulfate timing for preterm neuroprotection safe in each trimester?

• First trimester. Magnesium sulfate for fetal neuroprotection is not a routine first-trimester medicine. Its evidence concerns patients at imminent risk of very preterm birth later in pregnancy, not early pregnancy supplementation or oral magnesium products.
• Second trimester. Near the threshold of viability, use is individualized according to gestational age, likelihood and timing of birth, neonatal plans, contraindications, and local protocol. If birth is expected sooner than four hours, FIGO advises giving it rather than withholding solely for limited lead time.
• Third trimester. Before 32 weeks, ACOG patient guidance describes use when birth is expected within 24 hours. FIGO recommends use through 30 weeks and consideration below 32 to 34 weeks, so the upper boundary varies by protocol and evidence interpretation.